Yurdaydın, CihanMarcellin, PatrickBonino, FerruccioLau, GeorgeFarci, PatriziaPiratvisuth, TeerhaJin, RuiLu, Zhi-MengWu, JianPopescu, MateiHadziyannis, Stephanos2021-10-212021-10-212009-06Marcellin, P. vd. (2009) "Sustained response of Hepatitis B e Antigen-Negative patients 3 years after treatment with Peginterferon Alfa-2a". Gastroenterology, 136(7), 2169-2179.0016-5085https://doi.org/10.1053/j.gastro.2009.03.006https://www.sciencedirect.com/science/article/abs/pii/S0016508509003771http://hdl.handle.net/11452/22425Background & Aims: Patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B treated with peginterferon alfa-2a with or without lamivudine achieve significantly higher 6-month posttreatment rates of response compared with those treated with lamivudine alone. The durability of <= 3-year posttreatment response was investigated in this study. Methods: Patients received peginterferon alfa-2a only (180 p,g once weekly; n = 177), in combination with lamivudine (100 mg daily; n = 179) or lamivudine alone (n = 181) for 48 weeks. A total of 315 patients (116, 114, and 85, respectively) participated in this posttreatment observational study. Results: Three years after treatment, the percentage of patients with normal alanine aminotransferase (ATL) was higher for patients treated with peginterferon alfa-2a (31%) than with lamivudine (18%; P = 0.032). Similarly, 28% of patients treated with peginterferon had hepatitis B virus (HBV) DNA levels 10,000 copies/mL versus 15% of patients treated with lamivudine (P = .039). Peginterferon alfa-2a treatment and high baseline ALT level were independent baseline predictors of long-term virologic response (P = .040 and P = .01, respectively). Of the patients who had been treated with a peginterferon alfa-2a-containing regimen, 8.7% cleared hepatitis B surface antigen (HBsAg; 44% of those with undetectable HBV at 3-year posttreatment follow-up) compared with none treated with lamivudine alone. Conclusions: Biochemical and virologic responses were sustained for 53 years in approximately 25% of patients given a 48-week course of peginterferon alfa-2a, with or without lamivudine. The increased rate of HBsAg clearance in patients with HBeAg-negative chronic hepatitis B supports the use of peginterferon alfa-2a as a first-line treatment.eninfo:eu-repo/semantics/closedAccessTerm-follow-upAdefovir dipivoxilUntreated patientsSerum hbsagHbeagInterferonLamivudineTherapyCearanceDiseaseGastroenterology & hepatologyArticle0002666591000202-s2.0-6644912113021692179136719303414Gastroenterology & hepatologyHepatitis B E Antigen; Entecavir; TelbivudineAlanine aminotransferaseHepatitis B(e) antigenLamivudinePeginterferon alpha2aVirus DNAAdultAlanine aminotransferase blood levelArticleControlled studyDrug dose regimenFemaleFollow upHepatitis BHepatitis B virusHumanMajor clinical studyMalePriority journalTreatment responseVirology